Worse survival than with combination carboplatin-paclitaxel regimens for vulnerable older patients with ovarian cancer.
For vulnerable older patients with ovarian cancer, single-agent carboplatin is less active, with worse survival, than combination carboplatin-paclitaxel regimens, according to a study published online April
